|
Market Closed -
Nasdaq
21:00:00 14/08/2025 BST
|
5-day change | 1st Jan Change | ||
| 100.99 USD | +0.01% |
|
-.--% | - |
| Market Cap | 3.32B 2.92B 2.77B 2.5B 4.71B 318B 4.78B 33.15B 12.76B 163B 12.47B 12.2B 522B | P/E 2023 |
-317x | P/E 2024 | 69.3x |
|---|---|---|---|---|---|
| Enterprise Value | 3.48B 3.06B 2.9B 2.62B 4.94B 333B 5B 34.71B 13.36B 170B 13.06B 12.77B 546B | EV / Sales 2023 |
1.55x | EV / Sales 2024 | 1.33x |
| Free-Float |
-
| Yield 2023 * |
-
| Yield 2024 | - |
| 30/09/25 | A CEO's Playbook For Navigating Crisis And Building Trust (Video) | AQ |
| 29/07/25 | Amedisys: Q2 Earnings Snapshot | AQ |
| 29/07/25 | Amedisys : Second Quarter 2025 Earnings Release Supplemental Slides | PU |
| 29/07/25 | Amedisys Reports Second Quarter 2025 Financial Results | AQ |
| 23/04/25 | Amedisys: Q1 Earnings Snapshot | AQ |
| 1 day | +0.01% |
| 3 years | 82.15 |  | 101.02 |
| 5 years | 69.36 | | 188.88 |
| 10 years | 34.58 | | 325.12 |
| Manager | Title | Age | Since |
|---|---|---|---|
Scott Ginn
DFI | Director of Finance/CFO | 57 | 05/10/2017 |
Keith Blanchard
CTO | Chief Tech/Sci/R&D Officer | - | - |
Denise Bohnert
CMP | Compliance Officer | 48 | 31/12/2016 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 14/08/25 | Issuer sale | Director | 9,818 | 0.0300% | ||
| 14/08/25 | Issuer sale | Director | 9,818 | 0.0300% | ||
| 14/08/25 | Issuer sale | Chief Executive Officer | 520,347 | 1.5886% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 2.24B 1.97B 1.87B 1.68B 3.17B 214B 3.22B 22.32B 8.59B 110B 8.4B 8.21B 351B | 2.35B 2.07B 1.96B 1.77B 3.33B 225B 3.38B 23.44B 9.02B 115B 8.82B 8.63B 369B |
| Net income | -9.75M -8.58M -8.13M -7.34M -13.84M -935M -14.02M -97.3M -37.44M -478M -36.6M -35.8M -1.53B | 43.23M 38.07M 36.07M 32.56M 61.37M 4.15B 62.17M 432M 166M 2.12B 162M 159M 6.79B |
| Net Debt | 361M 318M 301M 272M 512M 34.59B 519M 3.6B 1.39B 17.68B 1.35B 1.33B 56.69B | 156M 137M 130M 118M 222M 14.96B 224M 1.56B 600M 7.65B 586M 573M 24.52B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- AMED Stock
Select your edition
All financial news and data tailored to specific country editions
